A monthly pharma newsletter from consultancy Galenisys mixing first-person war stories from GMP auditing and quality work with short pieces on industry trends such as GLP-1 drugs and orexins. Readers get practical quality, contamination control and project management lessons alongside light market commentary.
Website: https://insights.galenisys.com/
Alex Kesin's blog-style newsletter examines biotech and drug development, from US-China competition in drug licensing to pharma share buybacks and the heavy-tailed revenue distributions shared by drugs and Hollywood films. Readers get long-form, opinionated analysis with data, historical context and wry commentary on industry dynamics.
A daily-style biopharma newsletter offering commentary on therapeutics, regulatory oversight and clinical trials, organised around weekday themes. Readers get a short, opinionated take on industry developments such as biosimilar choices, regulator priorities and upcoming conference data.
Detailed analyses of clinical trial readouts and regulatory milestones in biotech, covering mechanism, patient population, competitive landscape and commercial implications. Readers get investor-oriented assessments of individual drug programs such as tozorakimab, zilganersen and DTX301.
Vital Signs is a weekly email covering EU health policy, including EMA drug approvals, pharmaceutical industry competitiveness and EU health programmes. Its issues mostly summarise regulatory and political news from Brussels, with some reporting on industry and public health developments.
One short email a week with hand-picked newsletters from the index. Free, no spam, unsubscribe anytime.
